PDS Biotechnology Corporation
PDSBHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company carries a $42.5M market cap, placing it firmly in the micro-cap category. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Market Cap
$42.5M
Beta
1.58
P/E (TTM)
—
P/E (Fwd)
-1.63
EPS (TTM)
$-0.69
EPS (Fwd)
$-0.47
ROE
-254.1%
ROA
-50.5%
Cash
$21.7M
Total Debt
$15.9M
Free CF
-$15.2M
52W Change
-33.9%
Annual Financials
Cash vs Debt
Where PDSB stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, PDSB finished 16.67% below its 150-day moving average ($0.90) and 16.67% below its 200-day moving average ($0.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PDSB overbought or oversold?
At the July 15, 2026 close, PDSB's RSI(14) was 15.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $21.7M in cash and $15.9M in debt, PDSB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$15.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -254.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
PDS Biotechnology Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence PDS Biotechnology Corporation's trajectory.